Resumen de Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia: The LAPLACE-2 Randomized Clinical Trial

Jennifer G. Robinson, Bettina S. Nedergaard, Jonathan Fialkow

• Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.

  Objective To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.